Bicara Therapeutics Inc. (BCAX)
Nasdaq: BCAX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2024
Who owns Bicara Therapeutics Inc.
As filed with the SECHolders of 5% or more
5
RA Capital Management, L.P. holds 11.5% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Mar 2, 2026 says.
Directors and officers
20
report now, of 23 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Mar 2, 2026 · Common Stock, par value $0.0001 per share
Raymond Debbane
SCHEDULE 13G/A · filed Jul 31, 2025 · Common Stock, par value $0.0001 per share
Vestal Point Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · 6.5% in Feb 17, 2026
Deep Track Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value · 5.02% in Feb 12, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Common Stock
JANUS HENDERSON GROUP Ltd.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · reported falling below 5%, from 5.1% in May 15, 2026
Red Tree GP, LLC
SCHEDULE 13G/A · filed May 8, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Oct 7, 2026 · COMMON STOCK · reported falling below 5%, from 10.1% in Apr 8, 2026
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · reported falling below 5%, from 6.1% in Feb 5, 2026
What BCAX reports owning in othersstakes of 5% or more, and other ties
Bicara Therapeutics Inc. reports no stake in another company in the record.
Insider tradesForm 4
71sales
1purchases
71sales on a scheduled plan
4people selling
$13.0Msold, in dollars
$4.8Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 36 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Cohlhepp Ryan | President, COO & Interim CEO | 29 | $4.6M | 29 | 0 | $0 |
| Mazumdar Claire | Chief Executive Officer | 17 | $4.1M | 17 | 0 | $0 |
| Hyep Ivan | Chief Financial Officer | 17 | $3.2M | 17 | 0 | $0 |
| Raben David | Chief Medical Officer | 8 | $1.1M | 8 | 0 | $0 |
| Ra Capital Management, L.P. | director | 0 | $0 | 0 | 1 | $4.8M |